Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Receivables (2018 - 2025)

Aclaris Therapeutics (ACRS) has 8 years of Change in Receivables data on record, last reported at -$56000.0 in Q2 2025.

  • For Q2 2025, Change in Receivables fell 16.67% year-over-year to -$56000.0; the TTM value through Jun 2025 reached -$131000.0, down 23.58%, while the annual FY2024 figure was $20000.0, 110.75% up from the prior year.
  • Change in Receivables reached -$56000.0 in Q2 2025 per ACRS's latest filing, up from -$68000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $202000.0 in Q1 2023 and bottomed at -$255000.0 in Q2 2023.
  • Average Change in Receivables over 5 years is -$32111.1, with a median of -$44000.0 recorded in 2022.
  • The widest YoY moves for Change in Receivables: up 1920.0% in 2023, down 6475.0% in 2023.
  • A 5-year view of Change in Receivables shows it stood at -$188000.0 in 2021, then soared by 39.89% to -$113000.0 in 2022, then skyrocketed by 57.52% to -$48000.0 in 2023, then skyrocketed by 47.92% to -$25000.0 in 2024, then plummeted by 124.0% to -$56000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$56000.0 in Q2 2025, -$68000.0 in Q1 2025, and -$25000.0 in Q4 2024.